Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
NCT04590235Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by AstraZeneca. Primary endpoints: Adverse events up to 3 years, Area under the concentration-time curve from zero to the last measurable concentration and 2 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT04590235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590235.